Previous Meetings

GBCC 2023

Global Breast Cancer Conference 2023

09:00-10:15
Panel Discussion 1
How to Manage Old-aged Breast Cancer Patients?
Venue: RM 2(Vista 3)
  • Screening and Assessment of Breast Cancer in Older Women
    Chee Hao Lester Leong (Singapore General Hospital, Singapore)
  • Systemic Therapy for Older Breast Cancer Patients
    Jee Hyun Kim (Seoul National Univ. Bundang Hospital, Korea)
  • Surgical Therapy for Older Breast Cancer Patient
    Tristen Park (Yale School of Medicine, U.S.A.)
Education Session 1
Radiologist’s Perspectives on Neoadjuvant Systemic Therapy in Breast Cancer
Venue: RM 3(Walker Hall 1)
  • Causes of Over- and Underestimation of Tumor and Axillary LN After Neoadjuvant System Therapy
    Beatriu Reig (NYU Langone Health, U.S.A.)
  • Evaluation of Response to Neoadjuvant Systemic Therapy: Multiparametric Approach for Accurate Evaluation of Residual Tumor
    Masako Kataoka (Kyoto Univ., Japan)
  • How to Manage Residual Microcalcifications After Neoadjuvant Chemotherapy
    Sung Hun Kim (The Catholic Univ. of Korea, Seoul St. Mary's Hospital, Korea)
Symposium 1
Recent Strategies for ER+/HER2- Breast Cancer
Venue: RM 1(Vista 1+2)
  • Optimal Duration of Endocrine Therapy
    Polly Suk Yee Cheung (Hong Kong Sanatorium and Hospital, Hong Kong)
  • The Role of CDK4/6 Inhibitors in ER+/HER2- Early Breast Cancer
    Tadahiko Shien (Okayama Univ. Hospital, Japan)
  • ER+/HER2 Negative Premenopausal Breast Cancer- The Biomarker Way Forward
    Peter C. Dubsky (Hirslanden Klinik St. Anna, Switzerland)
Oral Presentation 1
Venue: RM 4(Walker Hall 2)
GBCC-SSO Joint Session
Management of Hereditary Breast Cancer - Global Perspectives of Surgical Oncologists
Venue: RM 5(Art Hall)
  • Management of Hereditary Breast Cancer in the U.S.
    Tolga Ozmen (Massachusetts General Hospital, U.S.A.)
  • Management of Hereditary Breast Cancer in Europe
    Isabel T. Rubio (Clinica Universidad de Navarra, Spain)
  • Management of Hereditary Breast Cancer in Asia
    Sung-Won Kim (Daerim St. Mary's Hospital, Korea)
10:30-11:45
Education Session 2
Genomic Assays and Treatment Decision
Venue: RM 3(Walker Hall 1)
  • Optimal Decisions on Adjuvant Endocrine and Chemotherapy Using Multigene Assays
    Chi-Cheng Huang (Taipei Veterans General Hospital, Taiwan)
  • Clinical Parameters as Alternatives to Genomic Assays
    Jong Won Lee (ASAN Medical Center, Korea)
  • Interpretation of Genomic Assays in Premenopausal Women
    Kevin Kalinsky (Winship Cancer Institute of Emory Univ., U.S.A.)
Panel Discussion 2
Various Considerations in Premenopausal Breast Cancer Patients
Venue: RM 2(Vista 3)
  • The Optimal Endocrine Combination with OFS
    Hee Jeong Kim (ASAN Medical Center, Korea)
  • Targeted Therapy for High-risk Patients and gBRCA Mutation Patients
    Hee Kyung Ahn (Gachon Univ. Gil Medical Center, Korea)
  • Prophylactic Mastectomy
    Eric Schneider (Yale School of Medicine, U.S.A.)
Symposium 2
HER2-Low as a Targetable Subset of Breast Cancer
Venue: RM 1(Vista 1+2)
  • Is HER2-Low Breast Cancer an Independent/Distinctive Subtype?
    Naoto Ueno (Univ. of Hawai'i Cancer Center, U.S.A.)
  • How to Identify HER2-Low Breast Cancer
    Hee Jin Lee (ASAN Medical Center, Korea)
  • Targeting HER2-Low and the Treatment Sequence
    Wei-Pang Chung (National Cheng Kung Univ. Hospital, Taiwan)
Oral Presentation 2
Venue: RM 4(Walker Hall 2)
GBCC-JBCS Joint Session
Holistic Management for Breast Cancer Patients in Pandemic Era
Venue: RM 5(Art Hall)
  • Present and Future Perspectives in Korea
    So-Youn Jung (National Cancer Center, Korea)
  • Present and Future Perspectives in Japan
    Akihiko Shimomura (National Center for Global Health and Medicine, Japan)
12:00-12:45
Plenary Lecture 1
Venue: RM 1(Vista 1+2)
  • A Revolution in the Making: How Antibody-Drug Conjugates are Transforming Breast Cancer Treatment
    Ian Krop (Yale School of Medicine, U.S.A.)
13:00-13:45
Satellite Symposium 1
MSD Korea
Venue: RM 1(Vista 1+2)
  • Pembrolizumab for More TOMORROWs in TNBC
    Yen-Shen Lu (National Taiwan Univ. Hospital, Taiwan)
14:00-14:45
Plenary Lecture 2
Venue: RM 1(Vista 1+2)
  • Fertility Issues in Young Breast Cancer Patients
    Sibylle Loibl (GBG Forschungs GmbH, Germany)
15:00-16:15
Panel Discussion 3
Optimal Surgical Treatment After Neoadjuvant Chemotherapy
Venue: RM 2(Vista 3)
  • Avoiding Breast Surgery in Patients with Radiologic Complete Response
    Christoph Tausch (Breast-Center Zurich, Switzerland)
  • De-escalation of Sentinel Lymph Node Biopsy in Patients with Radiologic Complete Response
    Shih-Che Shen (Chang Gung Memorial Hospital, Taiwan)
  • De-escalation of Radiotherapy in Patients Achieved Pathologically Complete Response
    Yeon-Joo Kim (National Cancer Center, Korea)
Oral Presentation 3
Venue: RM 4(Walker Hall 2)
Symposium 3
Beyond CDK4/6 Inhibitor: New Target and New Drugs
Venue: RM 3(Walker Hall 1)
  • Novel Oral SERD and its Implication in Clinical Practice
    Yen-Shen Lu (National Taiwan Univ. Hospital, Taiwan)
  • Treatment Strategy After Progression on CDK4/6 Inhibitor
    Nadia Harbeck (LMU Univ. Hospital, Germany)
  • New Targets Beyond CDK4/6 Inhibitor: Development in Progress
    Yong Wha Moon (CHA Bundang Medical Center, Korea)
GBCC-TBCS Joint Session
Making Evidences Together
Venue: RM 5(Art Hall)
  • Breast Cancer Registry from the Korean Breast Cancer Society
    Jaihong Han (National Cancer Center, Korea)
  • Nationwide Taiwanese Breast Cancer Study
    Ching-Hung Lin (National Taiwan Univ. Hospital, Taiwan)
  • Korean Breast Cancer Study Using National Insurance Big Data
    Sungmin Park (Chungbuk National Univ. Hospital, Korea)
16:30-17:45
Education Session 3
Special Issues in Young Women with Breast Cancer Treated with Radiotherapy
Venue: RM 2(Vista 3)
  • Breast Radiotherapy During Pregnancy
    Stefanie Corradini (Univ. Hospital, LMU Munich, Germany)
  • Risk of Contralateral Breast Cancer After Breast Radiotherapy in Young Women
    Seung Won Seol (Univ. of Pennsylvania, U.S.A.)
  • Heart Disease After Breast Radiotherapy in Young Women
    Ji Hyeon Joo (Pusan National Univ. Yangsan Hospital, Korea)
Symposium 4
Tailored Surgery in Early-stage Breast Cancer
Venue: RM 3(Walker Hall 1)
  • Individualized Surgical Extent and Lumpectomy Margin in Early-stage Breast Cancer: Does Tumor Histology and Subtype Matter?
    Naoki Hayashi (Showa Univ. School of Medicine, Japan)
  • The Role of Axillary Surgery for DCIS and Early-stage Breast Cancer
    Wonshik Han (Seoul National Univ. Hospital, Korea)
  • Pre-operative Genomic Assay for Breast Surgery Guidance in HR+/HER2- Breast Cancer
    Caroline Drukker (Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Netherlands)
Oral Presentation 4
Venue: RM 4(Walker Hall 2)
GBCC-CACA Joint Session
Programs for Breast Cancer Screening and Prevention
Venue: RM 5(Art Hall)
  • KBCS Guidelines of Screening and Current Status
    Young-Joon Kang (The Catholic Univ. of Korea, Incheon St. Mary's Hospital, Korea)
  • CACA Guidelines of Screening and Current Status
    Yongsheng Wang (Shandong Cancer Hospital & Institute, China)
  • Korean Recommendations for Prevention and Risk Managements
    Yoo Seok Kim (Chosun Univ. Hospital, Korea)
  • Chinese Recommendations for Prevention and Risk Managements
    Junjie Li (Fudan Univ. Shanghai Cancer Center, China)
Back to Previous Meetings